Temel Tirkes1, Peter Mehta, Alex M Aisen, Chandana Lall, Fatih Akisik. 1. From the *Department of Radiology and Clinical Sciences, Indiana University School of Medicine, Indianapolis, IN; and †Department of Radiology, University of California, Irvine, Orange, CA.
Abstract
OBJECTIVE: To determine the differences in enhancement of hepatocellular carcinoma during the first 5 minutes of postcontrast phases with gadoxetic acid (Gd-EOB-DTPA) vs gadobenate dimeglumine. METHODS: Ninety-five cirrhotic patients with hepatocellular carcinoma were examined on a 1.5-T scanner: 74 patients with Gd-BOPTA and 21 patients with Gd-EOB-DTPA. Same magnetic resonance imaging parameters were used for both groups. Gadoxetate isodium was administered at a dose of 0.025 mmol/kg; and Gd-BOPTA, at a dose of 0.1 mmol/kg. RESULTS: Mean contrast-to-noise ratios (CNR) were similar in arterial (P = 0.3), portal venous (P = 0.1), and 5-minute delayed phases (P = 0.73). The CNRs of lesions in the Gd-EOB-DTPA group were lower in arterial phase, although this did not reach statistical significance. The CNRs of Gd-EOB-DTPA during the equilibrium phase was higher (P = 0.006). CONCLUSIONS: Gadoxetate isodium resulted in lower CNR during the arterial phase and higher CNR during the portal venous, equilibrium, and 5-minute delayed phases compared with gadobenate dimeglumine using the Food and Drug Administration-approved doses; however, overall, there was no statistical significance (P = 0.077).
OBJECTIVE: To determine the differences in enhancement of hepatocellular carcinoma during the first 5 minutes of postcontrast phases with gadoxetic acid (Gd-EOB-DTPA) vs gadobenate dimeglumine. METHODS: Ninety-five cirrhoticpatients with hepatocellular carcinoma were examined on a 1.5-T scanner: 74 patients with Gd-BOPTA and 21 patients with Gd-EOB-DTPA. Same magnetic resonance imaging parameters were used for both groups. Gadoxetate isodium was administered at a dose of 0.025 mmol/kg; and Gd-BOPTA, at a dose of 0.1 mmol/kg. RESULTS: Mean contrast-to-noise ratios (CNR) were similar in arterial (P = 0.3), portal venous (P = 0.1), and 5-minute delayed phases (P = 0.73). The CNRs of lesions in the Gd-EOB-DTPA group were lower in arterial phase, although this did not reach statistical significance. The CNRs of Gd-EOB-DTPA during the equilibrium phase was higher (P = 0.006). CONCLUSIONS:Gadoxetate isodium resulted in lower CNR during the arterial phase and higher CNR during the portal venous, equilibrium, and 5-minute delayed phases compared with gadobenate dimeglumine using the Food and Drug Administration-approved doses; however, overall, there was no statistical significance (P = 0.077).
Authors: Andrea Agostini; Moritz F Kircher; Richard K G Do; Alessandra Borgheresi; Serena Monti; Andrea Giovagnoni; Lorenzo Mannelli Journal: Semin Roentgenol Date: 2016-05-30 Impact factor: 0.800
Authors: Jimi Huh; So Yeon Kim; Benjamin M Yeh; Seung Soo Lee; Kyoung Won Kim; En-Haw Wu; Z Jane Wang; Li-qin Zhao; Wei Chou Chang Journal: Korean J Radiol Date: 2015-10-26 Impact factor: 3.500